Cargando…
ACSL4: biomarker, mediator and target in quadruple negative breast cancer
Breast cancer is a heterogeneous disease for which effective treatment depends on correct categorization of its molecular subtype. For the last several decades this determination has relied on hormone receptor status for estrogen, progesterone and HER2. More recently, gene expression data have been...
Autor principal: | Monaco, Marie E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259258/ https://www.ncbi.nlm.nih.gov/pubmed/37306503 http://dx.doi.org/10.18632/oncotarget.28453 |
Ejemplares similares
-
ACSL3 and ACSL4, Distinct Roles in Ferroptosis and Cancers
por: Yang, Yufei, et al.
Publicado: (2022) -
Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention
por: Jinna, Nikita, et al.
Publicado: (2022) -
Quadruple-negative breast cancer: novel implications for a new disease
por: Bhattarai, Shristi, et al.
Publicado: (2020) -
ACSL4 promotes prostate cancer growth, invasion and hormonal resistance
por: Wu, Xinyu, et al.
Publicado: (2015) -
Quadruple-Negative Breast Cancer: An Uneven Playing Field
por: Saini, Geetanjali, et al.
Publicado: (2020)